Patents by Inventor Anand Gautam
Anand Gautam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11954066Abstract: An identification of a new primary snapshot created for a primary storage system is received. A change tracking time window that is at least a portion of a period between a first capture time associated with a previous primary snapshot and a second capture time associated with the new primary snapshot is determined. Entries of a storage log of the primary storage system occurring within the change tracking time window are analyzed to coalesce changes identified in the entries of the storage log occurring within the change tracking time window into a change tracking result set. The change tracking result set is used to identify at least a portion of data changes between the previous primary snapshot and the new primary snapshot to capture in a new backup snapshot stored at a secondary storage system.Type: GrantFiled: July 21, 2021Date of Patent: April 9, 2024Assignee: Cohesity, Inc.Inventors: Amandeep Gautam, Anand Arun, Debasish Garai, Rupesh Bajaj, Himanshu Mehra, Vairavanathan Emalayan, Apurv Gupta
-
Patent number: 7820633Abstract: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.Type: GrantFiled: May 19, 2003Date of Patent: October 26, 2010Assignee: BN Immunotherapeutics, Inc.Inventors: Lucilla Steinaa, Jesper Haaning, Iben Dalum, Peter Birk, Dana Leach, Klaus Gregorius Nielsen, Gunilla Karlsson, Anand Gautam, Søren Mouritsen
-
Patent number: 7807441Abstract: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.Type: GrantFiled: August 11, 2005Date of Patent: October 5, 2010Assignee: BN Immunotherapeutics, Inc.Inventors: Lucilla Steinaa, Søren Mouritsen, Anand Gautam, Iben Dalum, Jesper Haaning, Dana Leach, Klaus Gregorius Nielsen, Gunilla Karlsson, Peter Birk Rasmussen
-
Patent number: 7005498Abstract: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.Type: GrantFiled: October 5, 1999Date of Patent: February 28, 2006Assignee: Pharmexa A/sInventors: Lucilla Steinaa, Søren Mouritsen, Anand Gautam, Iben Dalum, Jesper Hanning, Dana Leach, Klaus Gregorius Nielsen, Gunilla Karlsson, Peter Birk Rasmussen
-
Publication number: 20060008465Abstract: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.Type: ApplicationFiled: August 11, 2005Publication date: January 12, 2006Applicant: PHARMEXA A/SInventors: Lucilla Steinaa, Soren Mouritsen, Anand Gautam, Iben Dalum, Jesper Hanning, Dana Leach, Klaus Nielsen, Gunilla Karlsson, Peter Rasmussen
-
Publication number: 20040156838Abstract: The present invention discloses methods for immunizing against autologous (self) Immunoglobulin E (IgE). In particular, the invention discloses methods for inducing cytotoxic T-lymphocytes that will specifically down-regulate B-cells producing autologous IgE, notably by means of nucleic acid vaccination or live vaccination. Also disclosed are methods for inducing antibodies reactive with autologous IgE as well as methods for inducing a combined antibody and CTK response specific for IgE. The invention also discloses specific immunogenic protein constructs, nucleic acids encoding these as well as various formulations and tools for preparing the vaccines, including vectors and transformed host cells.Type: ApplicationFiled: March 6, 2003Publication date: August 12, 2004Inventors: Steen Klysner, Paul Von Hoegen, Bjorn Voldborg, Anand Gautam
-
Publication number: 20040141958Abstract: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.Type: ApplicationFiled: May 19, 2003Publication date: July 22, 2004Applicant: M&E Biotech A/SInventors: Lucilla Steinaa, Soren Mouritsen, Anand Gautam, Jesper Haaning, Iben Dalum, Peter Birk, Dana Leach, Klaus Gregorius Nielsen, Gunilla Karlsson
-
Publication number: 20040037840Abstract: The present invention relates to a novel method and formulation for the induction of immune responses against polypeptide antigens. In particular, the invention provides a method and formulation for induction of cytotoxic T cell responses against a polypeptide antigen of choice. The formulations are characterized by containing chitosan in admixture with the polypeptide antigen, preferably in the form of microparticles that may be cross-linked.Type: ApplicationFiled: October 26, 2001Publication date: February 26, 2004Inventors: Anne Mette Beier, Anand Gautam, Soren Mouritsen
-
Publication number: 20020172673Abstract: The present invention discloses methods for immunizing against autologous (self) Immunoglobulin E (IgE). In particular, the invention discloses methods for inducing cytotoxic T-lymphocytes that will specifically down-regulate B-cells producing autologous IgE, notably by means of nucleic acid vaccination or live vaccination. Also disclosed are methods for inducing antibodies reactive with autologous IgE as well as methods for inducing a combined antibody and CTK response specific for IgE. The invention also discloses specific immunogenic protein constructs, nucleic acids encoding these as well as various formulations and tools for preparing the vaccines, including vectors and transformed host cells.Type: ApplicationFiled: September 6, 2001Publication date: November 21, 2002Applicant: Pharmexa A/SInventors: Steen Klysner, Paul von Hoegen, Bjorn Voldborg, Anand Gautam